Our pandemic podcast is ending, though the pandemic hasn’t ended around the world.
We understand how this will end. But who bears the risk that remains?
The traumas of the past year have left some people wrestling with an awful question: Am I still a good person?
Our tests will need frequent touch-ups to make sure that no mutations get past them.
Things are starting to look up, at least in the U.S., but we’re looking ahead at potential future worries.
Lots of your questions about the future after COVID-19 get answered, and one listener gives us a little history lesson.
Post-vaccination infections reveal how effective vaccines are—and which variants are sneaking past our defenses.
It’s time for more weapons in the shots-versus-virus arms race.
The Atlantic staff writer Ed Yong talks with James Hamblin and Maeve Higgins about the ways, large and small, in which we’ve all suffered.
The pandemic’s mental wounds are still wide open.
What difference could it make worldwide if the U.S. waived patents for vaccines?
The best job perk is self-determination.
The reputation of all COVID-19 vaccines hinges on improving perceptions of the Johnson & Johnson shot.
A long-COVID patient and an immunologist help us understand the mysterious condition.
Here’s how to find out if your workplace’s return-to-office plans are actually safe.
Months of exuberant hand-sanitizing and social isolation during the pandemic have changed our exposure to microbes, in ways good and bad.
The internet has decided that Pfizer is significantly cooler than Moderna—but why?
“One country’s crisis is every country’s crisis.”
Readjusting our ideas about what’s safe is going to take time.
Headaches, eye pain, nausea—her symptoms began last spring. No one knows exactly why, except that the pandemic is to blame.